Technology | Breast Imaging | July 18, 2016

Software tracks hundreds of key performance indicators to help providers deliver high-quality, personalized breast screening

Volpara Solutions, VolparaEnterprise software, breast imaging, performance

July 18, 2016 — Volpara Solutions last week announced the commercial launch of VolparaEnterprise software, which helps breast imaging providers deliver high-quality, personalized breast screening. The Microsoft Azure–based solution provides real-time quality assurance and performance monitoring through dynamic, interactive dashboards.

VolparaEnterprise software delivers key performance indicators (KPIs) for hundreds of performance and quality metrics. Rooted in Volpara's fundamental scientific understanding of breast anatomy and imaging technologies, the VolparaEnterprise ConstantQuality metrics are updated with every mammography or tomosynthesis exam. The software enables breast imaging providers to perform rapid quality control checks to optimize the productivity and efficiency of imaging resources, to help reduce costs through the reduction of retakes, to increase staff effectiveness, and to provide objective evidence to demonstrate compliance and quality of care.

Examples of how VolparaEnterprise software has already helped sites improve productivity, quality assurance and cancer detection rates, include the following:

A facility discovered that a mammography system was using an incorrect dose setting, overexposing patients compared to the same machine type and same patient body habitus in similar facilities;
A facility discovered that it did not need to purchase an additional mammography machine because the software demonstrated that utilization was below the break-even point; and
One site told Volpara, "Your initial report was what prompted discussion, but being able to navigate around and see that out of 900 dose alerts they were all from the same unit was priceless."

VolparaEnterprise software is designed to scale to handle both large and small enterprises, whether located entirely in one site or across many. With a central database, users can securely access their dashboard from any browser or mobile device to be able to contrast and compare performance in each facility or view quality and performance metrics in aggregate.

"VolparaEnterprise software offers the first comprehensive tool to analyze clinical, quality and business data that impact nearly every aspect of a breast imaging practice. There is a tremendous amount of data that we've never been to access easily. The ability to track trends for hundreds of quality metrics over time can dramatically enhance our ability to maintain quality patient care as well as reduce the amount of time our staff spends on quality assurance," said Bruce F. Schroeder, M.D., Carolina Breast Imaging Specialists in Greenville, N.C.

VolparaEnterprise software provides Clinical Quality Measures (CQMs1) sought by payers to justify supplemental screening. The objective assessment of volumetric breast density helps reduce time spent by radiologists and technologists on recalls that are not clinically beneficial, such as ultrasound on Breast Imaging-Reporting and Data Systems (BI-RADS) A/B breasts inadvertently deemed "dense" due to subjective assessment of density. This not only results in better patient care, but preserves proper equipment utilization and staff workflow and productivity.

Researchers from the Netherlands used VolparaEnterprise to complete a study investigating the relationship between pressure applied during compression of the breast and screening performance. Results of the study, "Performance of breast cancer screening depends on mammographic compression, suggest high pressure reduces detectability of breast cancer," were recently presented at the International Workshop on Breast Imaging (IWDM) 2016. Results demonstrated that cancers detected and PPV were optimal in the middle compression category (9.18 to 10.71 kPa). These results can have significant implications for how breast screening is performed. It is known that under-compression leads to poor image quality; however, this study shows that pain is not the only adverse outcome of over-compression. With an almost two extra cancers per 1,000 detected at the medium pressure compared to the extremes, the effect of compression on cancer detection was significant and suggests that over-compression may affect tumor visibility. Researchers conclude that both under- and over-compression have undesirable effects in the context of the Dutch breast screening program, and pressure is an important metric to take into account.

For more information: www.volparasolutions.com


Related Content

News | Radiology Business

May 6, 2024 — ScreenPoint Medical’s Board of Directors has announced the appointment of Peter Kroese as the new Chief ...

Time May 06, 2024
arrow
News | Mammography

May 6, 2024 — Enable Me, a VELA Medical company, cited major new research by Siemens Healthineers entitled, “The future ...

Time May 06, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

One on One interviews with radiology trailblazers and historic FDA clearances made the top-read list for April. Take a ...

Time May 03, 2024
arrow
Feature | Breast Density | By Robert L. Bard, MD

Decades since the advent of breast scanning technology, innovations in noninvasive diagnostic imaging provide new ...

Time May 03, 2024
arrow
News | Breast Imaging

May 1, 2024 — Hologic, Inc., a global leader in women’s health, today announced that it signed a definitive agreement to ...

Time May 01, 2024
arrow
News | Breast Imaging

May 1, 2024 — The American College of Radiology (ACR) has issued a statement on the newly released Final USPSTF Breast ...

Time May 01, 2024
arrow
News | Breast Imaging

May 1, 2024 — After the issuance of updated breast screening recommendations by the U.S. Preventive Services Task Force ...

Time May 01, 2024
arrow
Feature | Breast Imaging | Christine Book

April 30, 2024 — The U.S. Preventive Services Task Force (Task Force) today published a final recommendation statement ...

Time April 30, 2024
arrow
Feature | Breast Imaging | By Christine Book

From implementing artificial intelligence effectively, advocating for radiologists, and working tirelessly to expand ...

Time April 29, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
Subscribe Now